21-gene recurrence score test (Oncotype DX)

The 21-gene recurrence score test, known as Oncotype DX, helps predict how likely early-stage breast cancer is to come back and whether a patient will benefit from chemotherapy. It analyzes the activity of 21 specific genes in tumor tissue to generate a score ranging from low to high risk. A low score suggests the cancer is less likely to recur and may not require chemotherapy, while a high score indicates a higher risk and potential benefit from additional treatment. This test aids doctors and patients in making more personalized, informed treatment decisions.